Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use

European Respiratory Journal

Volumn 50, Issue 1, 2017, Pages

  Hafkin, Jeffrey ^a   Hittel, Norbert ^b   Martin, Alexandra ^b   Gupta, Rajesh ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b Otsuka Novel Products GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; BEDAQUILINE; CAPREOMYCIN; CARBAPENEM; CLOFAZIMINE; DELAMANID; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; QUINOLONE DERIVATIVE; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; ASIA; BODY WEIGHT; CAUSE OF DEATH; CHILD; COHORT ANALYSIS; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EASTERN EUROPE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; HYPOKALEMIA; INFORMATION PROCESSING; INFORMED CONSENT; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PERSONAL EXPERIENCE; QT PROLONGATION; TREATMENT DURATION; TREATMENT OUTCOME; COMMUNICABLE DISEASE CONTROL; COMPASSIONATE USE; GLOBAL HEALTH; MIDDLE AGED; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CHILD; COMMUNICABLE DISEASE CONTROL; COMPASSIONATE USE TRIALS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; GLOBAL HEALTH; HUMANS; MALE; MIDDLE AGED; NITROIMIDAZOLES; OXAZOLES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 85045130450     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00311-2017     Document Type: Letter

References (16)

1. World Health Organization. Global tuberculosis report 2016. WHO/HTM/TB/2016.13. Geneva, World Health Organization, 2016.
2. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
3. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
4. Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 2012; 205: Suppl. 2, S241-S249.
5. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Eng J Med 2012; 366: 2151-2160.
6. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
7. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. WHO/HTM/TB/2014.23. Geneva, World Health Organization, 2014.
8. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014; 44: 811-815.
9. Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med 2015; 3: 201-209.
10. Wells CD, Gupta R, Hittel N, et al. Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid. Eur Respir J 2015; 45: 1498-1501.
11. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375: 1920-1937.
12. Jeon DS, Kim DH, Kang HS, et al. Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2009; 13: 594-600.
13. Gupta R, Geiter LJ, Wells CD, et al. Delamanid for extensively drug-resistant tuberculosis. N Engl J Med 2015; 373: 291-292.
14. Gupta R, Wells CD, Hittel N, et al. Delamanid in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2016; 20: S33-S37.
15. Horsburgh CR Jr, Haxaire-Theeuwes M, Lienhardt C, et al. Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013; 17: 146-152.
16. Bloemberg GV, Keller PM, Stucki D, et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Eng J Med 2015; 373: 1986-1988.